Regulation of tumour necrosis factor α mRNA stability by the mitogen-activated protein kinase p38 signalling cascade  by Brook, Matthew et al.
Regulation of tumour necrosis factor K mRNA stability by the
mitogen-activated protein kinase p38 signalling cascade
Matthew Brook, Gareth Sully, Andrew R. Clark*, Jeremy Saklatvala
Kennedy Institute of Rheumatology Division, Imperial College School of Medicine, 1 Aspenlea Road, Hammersmith, London W6 8LH, UK
Received 17 August 2000; accepted 14 September 2000
Edited by Marco Baggiolini
Abstract The translation of tumour necrosis factor K (TNFK)
mRNA is regulated by the stress-activated protein kinase p38,
which also controls the stability of several pro-inflammatory
mRNAs. The regulation of TNFK gene expression in a mouse
macrophage cell line RAW264.7 was re-examined using an
inhibitor of stress-activated protein kinases. Stimulation of these
cells with bacterial lipopolysaccharide resulted in stabilisation of
TNFK mRNA, which was reversed by specific inhibition of p38.
An adenosine/uridine-rich element from the TNFK 3P untrans-
lated region conferred p38-sensitive decay in a tetracycline-
regulated mRNA stability assay. Therefore the p38 pathway also
controls TNFK mRNA turnover. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Mitogen-activated protein kinase (MAPK) p38 is activated
by cell stresses such as heat shock or ultraviolet light and (in
cells of the myeloid lineage) by bacterial lipopolysaccharide
(LPS) [1]. The enzyme activity of p38 is reversibly inhibited by
pyridinyl imidazole compounds such as SB203580, which
compete with ATP for access to the catalytic site [2]. These
compounds inhibit interleukin 1 (IL-1) and tumour necrosis
factor K (TNFK) protein synthesis in myeloid cell lines stimu-
lated with LPS, but down-regulate the corresponding mRNAs
by 50% at most [3^5]. A mouse knock-out strain lacking the
p38 substrate MAPKAPK-2 displays defective translation of
TNFK mRNA [6]. These observations indicate a role for the
p38 pathway in the regulation of TNFK expression at the
translational level.
In contrast, an involvement of this signalling pathway in
the regulation of cyclooxygenase-2 (Cox-2) mRNA stability
has been demonstrated by actinomycin D chase experiments
in human monocytes and HeLa cells [7,8]. This was con¢rmed
using a tetracycline-responsive HeLa cell line [9], in which
chimeric L-globin/Cox-2 transcripts were stabilised by the ex-
pression of constitutively active MKK6 (an activator of p38)
[10,11] or MAPKAPK-2 (a downstream e¡ector of p38)
[12,13]. Similar experiments reveal regulation of IL-6 and
IL-8 mRNA stability by p38 [14].
The regulation of mRNA stability is often mediated by
adenosine/uridine-rich elements (AREs) within the 3P untrans-
lated regions (UTRs) of the transcripts in question [15,16].
The targeted deletion of a very similar ARE from the mouse
genomic TNFK locus causes an apparent increase in TNFK
mRNA stability, and a loss of the inhibitory e¡ects of
SB203580 upon TNFK biosynthesis [17]. The same ARE is
involved in the destabilisation of TNFK mRNA by the
RNA binding protein tristetraproline [18,19], which in turn
is regulated by the p38 pathway (in preparation). To address
the confusion over the regulation of mRNA turnover and
translation by the p38 pathway, we re-examined the expres-
sion of the TNFK gene in the mouse myeloid cell line
RAW264.7.
2. Materials and methods
2.1. Materials
GST-cJun1^135, His-tagged MAPKAPK-2 and a rabbit antiserum
to a C-terminal peptide of p38K are described elsewhere [7]. Recombi-
nant human hsp27 was from StressGen. Sheep anti-rabbit MAP-
KAPK-2 antibody was from Upstate Biotechnology. SB203580 was
from Calbiochem-Novabiochem. [Q-32P]ATP (3000 Ci/mmol), [K-
32P]dCTP (3000 Ci/mmol), [K-32P]UTP (800 Ci/mmol), Ready To
Go DNA labelling kit, Hybond XL membrane, Microspin S-200
HR columns and a Mono Q column were from Amersham Pharmacia
Biotech. Salmonella typhimurium LPS was from Sigma-Aldrich, and
was used throughout at a concentration of 10 ng/ml. DNase I was
from Life Technologies, RNeasy kits and Superfect transfection re-
agent were from Qiagen, and pBluescript plasmid and Stratalinker
UV cross-linker were from Stratagene. Murine GAPDH cDNA,
ULTRAhyb hybridisation bu¡er and Direct Protect ribonuclease pro-
tection assay reagents were from Ambion. T7 RNA polymerase and
T7 transcription bu¡er were from Boehringer Mannheim. Murine
TNFK enzyme-linked immunosorbent assay (ELISA) reagents were
from Pharmingen. The pTetBBB-TNF44 vector was constructed
from pTetBBB (gift of A. Shyu) by insertion of a double-stranded
oligonucleotide (upper strand sequence GATCCTTGTGATTATT-
TATTATTTATTTATTATTTATTTATTTACAGA) at the BglII
site within the L-globin 3P UTR. To generate pCRB-TNFr, a TNFK
cDNA fragment was ampli¢ed by reverse transcription-polymerase
chain reaction using primers GAAGCTGTCTTCAGACAGACATG
and GCCGGATCCGCGATCTTTATTTCTCTCAATTGACTGTA-
GG, then cloned into pCRBlunt (Invitrogen).
2.2. Cell culture
RAW 264.7 and HeLa Tet-o¡ cells were maintained in Dulbecco’s
modi¢ed Eagle’s medium/10% (v/v) foetal calf serum in a humidi¢ed
atmosphere of 5% (v/v) CO2 at 37‡C.
2.3. Kinase assays
Cells (2U106) were stimulated with 10 ng/ml LPS for the time
periods indicated, and lysates were prepared as described [7].
MAPK p38 was immunoprecipitated from 500 Wg of lysate, and ki-
nase assays were performed as described [7], using 1 Wg recombinant
MAPKAPK-2 as substrate. SB203580 is a reversible inhibitor of p38,
which is lost during washing of immunoprecipitates. To measure the
inhibition of p38 by SB203580, RAW264.7 cells were stimulated with
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10 ng/ml LPS for 20 min, the p38 substrate MAPKAPK-2 was im-
munoprecipitated and used in kinase assays with 1 Wg recombinant
hsp27 as described [7].
Cells (108) were stimulated for 20 min with 10 ng/ml LPS, then a
lysate was prepared and subjected to anion exchange chromatography
as described [7], except that a total of 2 mg of protein was chromato-
graphed. Fractions were assayed for cJun N-terminal kinase (JNK)
activity using GST-cJun1^135 substrate in the presence of vehicle (di-
methyl sulfoxide; DMSO) or SB203580 as indicated. Kinase activities
were quanti¢ed by phosphorimager (Fuji FLA2000; Fuji, Tokyo, Ja-
pan).
2.4. Measurement of TNFK protein and mRNA
TNFK protein was quantitated by ELISA as described [20]. Total
RNA was isolated using the RNeasy kit. Riboprobe was generated
from pCRB-TNFr by in vitro transcription as described [9]. A TNFK
cDNA probe was generated by random prime labelling of a 960 bp
SpeI^SspI fragment from pUC18mTNFloc. The GAPDH probe is
described elsewhere [7]. Northern blotting was performed as described
[7]. Where riboprobe was used, blots were washed at 65‡C in 2U, 1U
and 0.1USSC containing 0.1% SDS. Quantitation of mRNA was by
phosphorimager.
2.5. Transfection of HeLa Tet-o¡ cells, and ribonuclease protection
assays
Superfect was used to transfect HeLa Tet-o¡ cells with 100 ng
pGL3c, 100 ng pTetBBB-TNF44, with or without 100 ng of
pCMV-MKK6E and carrier DNA to a total of 1 Wg. After 24 h,
1 WM SB203580 or vehicle (DMSO) was added. After a further
30 min, tetracycline was added to a ¢nal concentration of 100 ng/
ml, and cells were harvested in Direct Protect lysis bu¡er at the
time intervals indicated. Ribonuclease protection assays were per-
formed as described [9], using riboprobes for L-globin and for endog-
enous GAPDH, and quanti¢ed by phosphorimager.
3. Results
3.1. Time course of activation of MAPK p38 by LPS
MAPK p38 activity was almost undetectable in unstimulat-
ed RAW264.7 cells, but was rapidly and strongly activated by
LPS treatment, with a peak of activity at 20 min post-stimulus
(Fig. 1). The activity subsequently declined, but remained sig-
ni¢cantly elevated above basal for at least 4 h after the stim-
ulus. E¡ects of p38 inhibition were later examined in cells treated with LPS for 4 h. In this context the sustained acti-
vation of p38 by LPS is signi¢cant. A similar pattern of acti-
vation of JNK was observed following LPS stimulation (data
not shown).
3.2. Dose responses of inhibition of p38 and JNK by SB203580
Inhibition of stress-activated protein kinases was measured
in extracts of LPS-stimulated RAW264.7 cells (Fig. 2A). As
expected, p38 was inhibited with an IC50 of approximately
0.1 WM. Two chromatographically distinct JNK fractions
were puri¢ed from these cells and contained approximately
equal activity (data not shown). Although much less sensitive
to SB203580 than p38, both were signi¢cantly inhibited at
higher doses of the inhibitor in vitro. Total JNK activity
was inhibited by 10, 25 and 60% at 0.1, 1.0 and 10 WM
SB203580. Inhibition of JNK isoforms by the ‘p38-speci¢c
inhibitor’ SB203580 has previously been reported [7,21,22],
but appears somewhat cell type speci¢c, and has not been
examined in RAW264.7 cells.
3.3. Di¡erential regulation of TNFK protein and mRNA
expression in RAW264.7 cells
The e¡ects of SB203580 upon TNFK protein and mRNA
accumulation were examined in RAW264.7 cells preincubated
for 1 h with the inhibitor, then stimulated for 4 h with LPS.
Fig. 1. Time course of activation of p38 by LPS. RAW264.7 cells
were stimulated with 10 ng/ml LPS for the times indicated, then
harvested. Immunoprecipitations were performed using an antiserum
to p38, except in the ¢rst track (marked with an asterisk), where
the corresponding pre-immune serum was used. Kinase assays were
then performed using the substrate MAPKAPK-2 (MK2).
Fig. 2. Inhibition of stress-activated protein kinases and TNFK gene
expression by SB203580. A: Inhibition of p38 in vivo (b) and of
two chromatographic peaks of JNK activity in vitro (F and R) was
measured in triplicate. Means þ S.D. are indicated. B: RAW264.7
cells were stimulated for 4 h with 10 ng/ml LPS, then TNFK
mRNA (closed bars) and protein (open bars) were quanti¢ed.
Means þ S.D. of three independent experiments are indicated.
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TNFK mRNA expression was inhibited by around 50% at
most, even at a 10 WM concentration of SB203580 (Fig.
2B). Protein expression was more strongly inhibited, with an
IC50 close to 0.1 WM. The di¡erential regulation of protein
and mRNA expression at higher doses of SB203580 is con-
sistent with translational regulation of TNFK gene expression.
However it is di⁄cult to be certain whether this is mediated
entirely by p38, or whether a signi¢cant role is played by JNK
[23].
3.4. Regulation of TNFK mRNA stability by SB203580
At 0.1 or 1.0 WM concentration SB203580 partially, but
reproducibly, blocked the accumulation of TNFK mRNA in
response to an LPS challenge. In preliminary experiments
(data not shown) we found no evidence for the regulation
of TNFK gene transcription by SB203580, therefore the reg-
ulation of TNFK mRNA stability by the p38 pathway was
examined. In unstimulated cells TNFK mRNA could be de-
tected by Northern blotting with a high speci¢c activity ribo-
probe. Decay of this transcript was rapid and insensitive to
SB203580 (Fig. 3A). In cells stimulated for 4 h with LPS, the
stability of TNFK mRNA was greater, but was decreased
signi¢cantly by 0.1 WM, and very strongly by 1.0 or 10 WM
SB203580 (Fig. 3A,B). The estimated transcript half-lives were
26, 60 and 11 min in unstimulated cells, in stimulated cells and
in stimulated cells treated with 1 WM SB203580. This suggests
an LPS-responsive stabilisation of TNFK mRNA, which is
dependent upon p38. Such stabilisation can be detected within
30 min of LPS treatment (data not shown).
To address the possibility that regulation of mRNA stabil-
ity by p38 is an actinomycin D artefact, e¡ects of SB203580
upon TNFK mRNA levels were examined in the absence of
actinomycin D, following stimulation of cells for 4 h with LPS
(Fig. 4). In the absence of SB203580, TNFK mRNA levels
remained roughly constant over 1 h, suggesting that transcrip-
tion and degradation rates were approximately balanced dur-
ing this time. Following the addition of the inhibitor, steady
state TNFK mRNA levels rapidly decreased to about 50% of
their starting level but no further, suggesting that degradation
of TNFK mRNA is p38-sensitive in the absence of actino-
mycin D.
Fig. 3. p38 regulates the stability of TNFK mRNA. A: RAW264.7
cells were treated with actinomycin D (AmD, 10 Wg/ml) in the pres-
ence of SB203580 or vehicle, harvested at the time intervals shown,
and Northern blotted for TNFK mRNA using a high speci¢c activ-
ity riboprobe. B: RAW264.7 cells were stimulated with 10 ng/ml
LPS for 4 h, then actinomycin D (AmD, 10 Wg/ml) was added in
the absence or presence of SB203580 as indicated, cells were har-
vested at the time intervals shown and Northern blots were done
using a TNFK cDNA probe. C: Mean TNFK mRNA levels, cor-
rected for GAPDH mRNA, from three independent experiments
performed as in B, using a 1 WM dose of SB203580. a,
3SB203580; b, +SB203580. Error bars indicate S.D.
Fig. 4. SB203580 down-regulates TNFK mRNA in the absence of
actinomycin D. A: RAW264.7 cells were stimulated for 4 h with
10 ng/ml LPS, then treated with 1 WM SB203580 or vehicle
(DMSO). At the time intervals shown, cells were harvested and
Northern blots performed using a TNFK cDNA probe. B: Mean
TNFK mRNA levels, corrected for GAPDH mRNA, from three in-
dependent experiments performed as in A. a, 3SB203580; b,
+SB203580. Error bars indicate S.D.
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3.4. An ARE derived from the TNFK 3P UTR mediates
regulation of mRNA stability by the MAPK p38 cascade
To further analyse the regulation of TNFK mRNA stabil-
ity, a tetracycline-regulated reporter gene system [24,25] was
employed (Fig. 5). In HeLa Tet-o¡ cells L-globin mRNA was
expressed under the control of a tetracycline-responsive pro-
moter, which can be switched o¡ by addition of 100 ng/ml
tetracycline to the culture medium. Decay of the L-globin
mRNA was scarcely detectable under these conditions (data
not shown). The insertion of a short (44 nt) TNFK adenosine/
uridine-rich stretch resulted in the destabilisation of the
L-globin reporter mRNA. The chimeric L-globin-TNF44
mRNA was stabilised by coexpression of the p38 activator
MKK6, and this stabilisation was reversed upon addition of
SB203580. The increased L-globin-TNF44 mRNA seen at the
zero time point in the presence of MKK6 is the consequence
of stabilisation during the 24 h prior to the tetracycline chase.
MAPK p38-responsive mRNA instability was not conferred
by a fragment containing ¢ve overlapping AUUUA motifs
(data not shown), and is therefore not a general feature of
AREs. Although TNFK mRNA is not normally expressed by
HeLa cells, these observations clearly demonstrate that the
transcript contains p38-responsive stability determinants.
4. Discussion
Both JNK and p38 signal transduction pathways were acti-
vated in LPS-stimulated RAW264.7 cells, but were di¡eren-
tially inhibited by SB203580. E¡ects observed at high concen-
trations of SB203580 cannot safely be ascribed to p38
inhibition, because of signi¢cant inhibition of JNK activity
under these conditions. Thus, the di¡erential regulation of
TNFK gene expression at protein and mRNA levels is consis-
tent with translational control, however this may be mediated
in part by JNKs [23]. In the absence of reliable assays of
translational control in vivo, the contributions of the two
stress-activated protein kinase pathways are di⁄cult to assess.
In contrast, TNFK mRNA was clearly destabilised by 1 WM
SB203580, strongly implicating p38 in the regulation of TNFK
mRNA stability. Several observations suggest that this is not
an artefact arising from the use of actinomycin D. In actino-
mycin D chase experiments the stability of TNFK mRNA was
increased by LPS treatment of cells. Stability was sensitive to
p38 inhibition only in LPS-stimulated cells, therefore
SB203580 does not simply interfere with an artifactual stabi-
lisation caused by actinomycin D. Whilst there was no evi-
dence for an involvement of p38 in the LPS-stimulated tran-
scription of the TNFK gene, SB203580 signi¢cantly down-
regulated steady state TNFK mRNA levels in the absence of
actinomcyin D, implying an e¡ect upon mRNA stability.
SB203580 in£uenced TNFK mRNA stability in the presence
of K-amanitin, a transcriptional inhibitor which is functionally
distinct from actinomycin D (data not shown). Finally, a
short adenosine/uridine-rich fragment of the TNFK 3P UTR
conferred p38-responsive mRNA instability in HeLa cells. It
is possible that changes in TNFK mRNA stability in
RAW264.7 cells are masked by ongoing transcription, which
is not sensitive to SB203580, resulting in the relatively minor
di¡erences at the steady state mRNA level which are de-
scribed here and elsewhere [5].
Both translation and mRNA stability are coupled to the
regulation of poly(A) tail length [26]. Deadenylation is impli-
cated in the regulation of TNFK mRNA stability by both
TTP and the protein kinase C pathway [19,27,28]. In the
absence (Fig. 3B) or presence (Fig. 4) of actinomycin D, the
addition of SB203580 appeared to be followed by a rapid
shortening of the TNFK transcript. It remains to be shown
that this corresponds to the shortening or removal of the
poly(A) tail, however the regulation of poly(A) tail length
by the p38 pathway may provide an explanation for the ap-
parent regulation of translation or of mRNA stability by the
p38 pathway in di¡erent studies.
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